Category
Longevity
Peptides and peptide-adjacent compounds aimed at the biology of aging itself: mitochondrial function, cellular energy metabolism, telomere maintenance, immune aging. Not tied to any single organ or symptom.
Category primer
Almost everything here is early-stage: strong mouse and cell-culture mechanistic stories (MOTS-c, Humanin, NAD+ precursors) with essentially no rigorous human longevity trial data, because human lifespan trials are extremely hard to run. Treat this category as promising mechanistic hypotheses currently being self-tested by early adopters, not established interventions.
PEPTIDES in this category
-
5-Amino-1MQ
NNMT inhibitor that redirects nicotinamide into NAD+ synthesis. Popular in biohacker circles, backed by zero human trials.
Research chemical -
Cardiogen
Organ-targeted bioregulator from the Khavinson lineage aimed at cardiac tissue repair.
Approved in Russia -
Cerebrolysin
Porcine neuropeptide preparation with clinical use for stroke and dementia in non-US countries.
Approved in 40+ countries; not FDA-approved in US -
Crystagen
Organ-targeted Khavinson peptide aimed at immune activation and B-cell function.
Approved in Russia; limited Western literature -
Epithalon
A synthetic tetrapeptide based on a natural pineal-gland extract, studied by Russian researchers for telomerase activation, sleep and immune aging.
Research chemical -
FOXO4-DRI
Senolytic peptide that disrupts the FOXO4-p53 interaction to induce selective apoptosis of senescent cells. Highly promising in mouse models, with minimal human evidence.
Research compound -
Humanin
A mitochondrial-derived peptide originally discovered for neuroprotection against Alzheimer's-related cell death, now explored in metabolic and longevity research.
Research chemical -
Liraglutide
First-generation GLP-1 receptor agonist, FDA-approved for weight loss (Saxenda) and diabetes (Victoza) with well-established safety and efficacy.
FDA-approved (2014 for diabetes, 2016 for weight loss) -
Mazdutide
Dual GLP-1/glucagon agonist in Phase 3 trials showing 15-20% weight loss with metabolic benefits beyond weight reduction.
Investigational (Phase 3) -
MOTS-c
Mitochondrial-derived peptide encoded in mitochondrial DNA, studied for metabolic regulation and exercise-mimetic effects.
Research chemical -
NAD+
Cellular coenzyme central to energy metabolism and DNA repair. Not actually a peptide, but a fixture of longevity peptide clinics and stacks.
Unregulated / not a peptide -
P21
CNTF-derived peptide with claimed neurogenic potential; adamantane-conjugated variant designed for blood-brain barrier penetration.
Investigational research compound -
PNC27
CANCER RESEARCH ONLY: p53-derived peptide inducing tumor cell necrosis through HDM-2 interaction; no human clinical trials, and no longevity or anti-aging protocol exists.
Preclinical oncology research only -
SLU-PP-332
A rodent-only 'exercise in a pill' compound that genuinely turns on exercise-like gene programs — but it is a small molecule, not a peptide, and has never been dosed in a human trial.
Research chemical -
SS-31
Mitochondria-targeted tetrapeptide that stabilizes cardiolipin and restores oxidative phosphorylation. FDA-approved for rare Barth syndrome, investigational in heart failure and aging-related conditions.
FDA Accelerated Approval (2025) for Barth Syndrome -
Survodutide
Boehringer Ingelheim's GLP-1/glucagon dual agonist in Phase 3, showing 17-22% weight loss with a cardiovascular outcomes trial underway.
Investigational (Phase 3) -
Thymalin
Thymic bioregulator from the Khavinson family with long-term human mortality follow-up and immune-modulating effects.
Approved in Russia and Eastern Europe -
Thymosin Alpha-1
A naturally occurring immune-regulating peptide, approved as a prescription drug (Zadaxin) in dozens of countries for chronic hepatitis B/C and as an immune adjuvant, one of the few peptides here with real regulatory approval somewhere in the world.
Approved abroad (Rx) -
Vesugen
Organ-targeted peptide supporting vascular endothelial cell function and tissue regeneration.
Approved in Russia; PubMed-indexed research available -
Vilon
Short-form thymic dipeptide bioregulator with immunomodulatory and T-cell differentiation effects.
Available in Russia and some Eastern European countries